PP_1170x120_10-25-21

Florida Pharmaceutical Products and Quinn Pharmaceuticals team

Print Friendly, PDF & Email

BOCA RATON, Fla. — Stason Pharmaceuticals, a global pharmaceutical group based in Irvine, Calif.  recently entered into a strategic alliance with Florida Pharmaceutical Products, (FPP) for Stason subsidiary Quinn Pharmaceuticals. Financial terms were not disclosed.

With strong business ties to pharmaceutical interests in Japan, Taiwan and China, Stason Pharmaceuticals, acquires and develops promising drug candidates originating in Asia and guides their manufacture, sale and distribution within the United States.

Florida Pharmaceutical Products, Inc., based here has experienced leadership with proven deal-closing expertise, a solid implementation track record, influential industry relationships and extensive resources to realize objectives with speed and efficiency.

According to Florida Pharmaceutical Products, president Larry Lapila, “The structure of this agreement supercharges the flow of generic pharmaceutical drugs from Asia to the United States and utilizes our skillset to create greater production, distribution and supply chain efficiencies for Stason and Quinn.”

Stason Pharmaceuticals, Inc., chief executive officer Harry Fan added, “The Quinn label, built by the Quinn team under the leadership of Gina Campbell, is recognized for quality and value. The new alliance with Florida Pharmaceutical Products, Inc., creates a continuous all-inclusive solution by fueling manufacturing options and also adding warehousing, logistics and order fulfillment to retail accounts. This framework improves results and provides the infrastructure for continued growth.”

This new arrangement merges capabilities to create an end-to-end solution for generic pharmaceutical development, manufacture, sales, marketing, distribution and supply chain logistics.

Florida Pharmaceutical Products, Inc., recently entered a strategic partnership with Woodfield Distribution to support FPP business expansion.


ECRM-08-202222


Comments are closed.